Session 1:  OPIOID USE DISORDER/PART 1 CE: 4 HRS 

September 30, 2017   12-4pm

I. About  MAT

II. OUD  Diagnostic Criteria per DSM-5

III. Biophysiology  of OUD and use of Medication Assisted Treatment

Session 2: OPIOID USE DISORDER/PART 2 CE: 4 HRS

October 14, 2017   12-4pm

I. Screening OUD patients for MAT

II. MAT Potential Risks vs. Potential Benefits Analysis

Session 3: OPIOID USE DISORDER/ PART 3 CE: 4 HRS

December 2, 2017   12-4pm

I. Interventions for OUD MAT Risk Reduction Strategies

II. Medical Factors MAT in Special Populations

Session 4: OPIOID USE DISORDER/PART 4 CE:  4 HRS

  January 6, 2018   12-4pm

I. Improving Outcomes with MAT  through:

II. Supporting Patient Choice of Recovery Support  Options

III. Helping patient and Family select treatment setting

IV. Stigma Reduction

Session 5: INTRO TO PSYCHIATRIC MEDICATIONS   CE:   5 HRS

April 14, 2018 12-5pm

I. Review  of Medications for OUD

a. Indications,  actions, side effects, warnings

II. Review of Medications for Sedative Use Disorders

a. Indications, actions, side effects, warnings

III. Review of Medications for Depression

a. Class of Anti-Depressant; Indications, actions, side effects, warnings

b. Natural  Non-Medical  Interventions

IV. Review of Medications for Bi-Polar Disorders

a. Indications, actions, side effects, warnings

V. Review of Medications for Schizophrenia

a. Indications, actions, side effects, warnings

VI. Review of Medications for Generalized Anxiety Disorders

a. Indications, actions, side effects, and warnings

VII. Need for ongoing medical consultation and how- to’s for Coordination of Care

Session 6:  ALCOHOL PHARMACOTHERAPY AND SEDATIVE HYPNOTIC AND AXIOLYTIC DISORDERS

May 19, 2018 11a-6pm CE:  6 HRS / Lunch Provided

I. Alcohol’s Effect on Brain

II. DSM-5 Criteria for AUD

III. Alcohol Use Risks

IV. Alcohol Withdrawal Risks/Management

V. Medications Used in AUD

VI. Special Populations who may benefit

V. Community OutReach Strategies to reduce Stigma

VI. Role of PCP/Medical Consultation

VII. Benzodiazapines

VIII. a. effect on brain

IX. b. DSM-5 diagnostic criteria

Session 7: MOTIVATION, CHANGE, AND S-BIRT

June 23, 2018 12-5pm CE: 5 Hrs.

I. Review of Professional Ethics

II.Rapport at the Core

III.Conducting Needs Assessment

IV.ASAM – Review of Readiness of Change Stages

V.Developing and Establishing Support Plan

VI.Engagement

VII.Patient Retention

VIII.Recognizing and Responding to Potential Crisis

IX.Develop and Maintain Recovery Partnerships

X.Four Principals of MI

XI.S-Birt

View MAT Flyer